Armata Pharmaceuticals Inc (A:ARMP)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 4503 Glencoe Ave
MARINA DEL REY CA 90292-6372
Tel: N/A
Website: https://www.armatapharma.com
IR: See website
<
Key People
Jeremy Laurence Curnock-Cook
Chairman of the Board
Brian Varnum
President, Chief Development Officer
Todd R. Patrick
Chief Executive Officer, Director
Steven Robert Martin
Chief Financial Officer
Igor P. Bilinsky
Chief Operating Officer, Senior Vice President
Duane Alfred Morris
Vice President - Operations
Heather Jones
Medical Director
   
Business Overview
Armata Pharmaceuticals, Inc., formerly AmpliPhi Biosciences Corporation, is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AB-SA01 and AB-PA01.
Financial Overview
For the fiscal year ended 31 December 2019, Armata Pharmaceuticals Inc revenues was not reported. Net loss increased 61% to $19.5M. Higher net loss reflects Other Research and development increase of 96% to $9M (expense), Stock-based Compensation in SGA increase from $152K to $3.4M (expense), Stock-based Compensation in R&D increase from $326K to $872K (expense).
Employees: 33 as of Mar 6, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $28.93M as of Dec 31, 2019
Annual revenue (TTM): $0.00M as of Dec 31, 2019
EBITDA (TTM): -$16.33M as of Dec 31, 2019
Net annual income (TTM): -$19.48M as of Dec 31, 2019
Free cash flow (TTM): -$15.81M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 10,927,032 as of Mar 5, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization